Kangstem Biotech Applies for Phase 3 Clinical Trial of PureSystem-AD Injection for Chronic Atopic Dermatitis
[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 29th that it has applied to the Ministry of Food and Drug Safety (MFDS) for a Phase 3 clinical trial to evaluate the efficacy and safety of PureSystem-AD injection in patients with moderate to severe chronic atopic dermatitis.
Hot Picks Today
"Who Would Buy an 'Ugly' Car?" Despite Harsh Reviews, All $920,000 Ferraris Already Sold Out
- "Down 17% — 'This Is Too Much'... Frustrated Shareholders Enter Politics Themselves"
- "Betrayal in a Cup of Iced Coffee"... Even 7,500 Won Coffee Not Spared from 'Contaminated Ice'
- "My Money Is Melting Away... Government Blamed for Turning Stock Market Into a Playground for Foreign Investors Amid Market Crash"
- "Licking a Straw Changed His Life: The Consequence for a 19-Year-Old's Vending Machine Prank"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
